Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| McEwen Inc.MUX · Entity 4867 | Director | December 31, 2023 | February 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
McEwen Inc.
Report date December 31, 2023 · Filed February 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.10 · Expires 2028-06-28 | Direct | 25,000 |
Reported balance
After 2023-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-29 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests in three equal annual installments, beginning June 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in three equal annual installments, beginning June 29, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2023 Filed Feb 14, 2024 21:19 UTC | McEwen Inc. MUX · Entity 4867 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001104659-24-023709 · tm246198-2_5seq1.xml · derivative · entry 1 AMBROSE ALLEN V · CIK 0001228611 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-28 F1 · derivative.exercise_date: The option vests in three equal annual installments, beginning June 29, 2024. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 23:00 UTC | McEwen Inc. MUX · Entity 4867 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001415889-20-002373 · form4-10012020_071001.xml · derivative · entry 1 AMBROSE ALLEN V · CIK 0001228611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2025-09-28 F1 · derivative.exercise_date: The option vests in three equal annual installments, beginning September 29, 2021. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:59 UTC | McEwen Inc. MUX · Entity 4867 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001179110-19-007606 · edgar.xml · derivative · entry 1 AMBROSE ALLEN V · CIK 0001228611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2024-06-10 F1 · derivative.exercise_date: The Option vests in three equal annual installments beginning June 11, 2020. Read SEC document |
| May 16, 2018 Filed May 17, 2018 20:19 UTC | McEwen Inc. MUX · Entity 4867 | PurchaseCommon Stock | 19,230 | $2.08 | $39,994.55 |
DisclosureSEC source: 0001179110-18-007023 · edgar.xml · nonDerivative · entry 1 AMBROSE ALLEN V · CIK 0001228611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,134 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.